Inactivation of viruses by delipidation

Patent metadata

Field	Value
Publication number	US-10420831-B2
Application number	US-201716060561-A
Country	US
Kind code	B2
Filing date	Jan 20, 2017
Priority date	Jan 27, 2016
Publication date	Sep 24, 2019
Grant date	Sep 24, 2019

Abstract

The present invention relates to vaccines containing enveloped viruses whose envelopes have been depleted of lipids using methyl β-cyclodextrin (MBCD). Delipidation of enveloped viruses in a two-step process abolishes the infectivity of those viruses, which allows delipidated viruses to be used safely in vaccines. Use of MBCD to deplete lipids such as cholesterol, in contrast to other methods, results in viruses with less than 20% of the cholesterol of an untreated virus but such delipidated viruses retain at least 85% of the protein content of an untreated virus. Delipidation by MBCD also preserves the immunogenicity of the viral proteins. The present invention of using MBCD treatment in a two-step process to delipidate enveloped virus represents a new alternative for generation of inactivated viruses which are incorporated into effective vaccines.

First claim

What is claimed is:

1. A method of preparing an inactivated enveloped virus comprising:
mixing a solution comprising an enveloped virus with a first methyl β-cyclodextrin (MBCD) solution to obtain a first mixture;
incubating the first mixture for a first time period;
mixing the enveloped virus from the first mixture with a second MBCD solution to obtain a second mixture; and
incubating said second mixture for a second time period.

2. The method of claim 1 wherein a concentration of MBCD in the first mixture is at least 5 mM to about 100 mM.

3. The method of claim 1 wherein a concentration of MBCD in the first mixture is about 20 mM to about 40 mM.

4. The method of claim 1 wherein a concentration of MBCD in the second mixture is about 10 mM to about 100 mM.

5. The method of claim 1 wherein a concentration of MBCD in the second mixture is about 30 mM to about 50 mM.

6. The method of claim 1 wherein the first time period is about 15 minutes to about 24 hours.

7. The method of claim 1 wherein the first time period is about 4 hours to about 24 hours.

8. The method of claim 1 wherein the second time period is about 4 hours to about 48 hours.

9. The method of claim 1 wherein the second time period is about 24 hours, about 36 hours, or about 48 hours.

10. The method of claim 1 wherein a temperature of at least one of the first time period and the second time period is about 20° C. to about 25° C.

11. The method of claim 10 wherein the temperature is about 22° C. to about 24° C.

12. The method of claim 1 wherein the enveloped virus is isolated from the first mixture prior to the step of obtaining the second mixture.

13. The method of claim 1 wherein the enveloped virus is Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

14. The method of claim 1 wherein at least one of the first time period and the second time period further comprises stirring of the first mixture and/or the second mixture.

15. A method of making a vaccine comprising:
mixing a solution comprising an enveloped virus with a first methyl β-cyclodextrin (MBCD) solution containing a concentration of MBCD of at least 5 mM to about 100 mM to obtain a first mixture;
incubating the first mixture for a first time period of about 15 minutes to about 24 hours;
mixing the enveloped virus from the first mixture with a second MBCD solution containing a concentration of MBCD of at least 10 mM to about 100 mM to obtain a second mixture;
incubating said second mixture for a second time period of about 4 hours to about 48 hours;
isolating the enveloped virus; and
combining the isolated enveloped virus with at least one of: an adjuvant, a stabilizer, a preservative, and a blending diluent;
wherein a temperature of at least one of the first time period and the second time period is about 20° C. to about 25° C.

16. The method of claim 15 wherein the enveloped virus is Porcine Reproductive and Respiratory Syndrome (PRRS) virus.

Assignees

• Lilly Co Eli
• Elanco Us Inc

Inventors

• Wu Stephen
• Diaz Leyla

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P31/12

  Antivirals · CPC title

• C12N2760/16134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title

• C12N2760/16151

  Methods of production or purification of viral material · CPC title